Case Study: Evaluation of Anticancer Treatment and Cardiovascular Safety in a Breast Cancer Patient with Pre-existing Cardiovascular Conditions - Scorecard - MDSpire
Advertisement
Case Study: Evaluation of Anticancer Treatment and Cardiovascular Safety in a Breast Cancer Patient with Pre-existing Cardiovascular Conditions
Clinical Scorecard: Evaluation of Anticancer Treatment and Cardiovascular Safety in a Breast Cancer Patient with Pre-existing Cardiovascular Conditions
At a Glance
Category
Detail
Condition
HER2-positive breast cancer with pre-existing cardiovascular comorbidities (hypertension, diabetes mellitus, coronary heart disease post-PCI)
Key Mechanisms
Cancer therapy-related cardiovascular toxicity (CTR-CVT) including cardiac dysfunction, hypertension, thrombosis; perioperative thrombotic and bleeding risk balancing; cardiotoxicity risk mitigation by regimen selection and monitoring
Target Population
Breast cancer patients with multiple cardiovascular risk factors, especially elderly with prior coronary artery disease
Care Setting
Multidisciplinary oncology and cardiology care including perioperative management and long-term cardiac monitoring
Key Highlights
Use of low-cardiotoxicity PTD regimen (pertuzumab, trastuzumab, docetaxel) to minimize cardiac risk in HER2-positive breast cancer patients with cardiovascular comorbidities
Perioperative antithrombotic management guided by PRECISE-DAPT and HAS-BLED scores with LMWH bridging and temporary antiplatelet discontinuation
Continuous cardiac function monitoring (biomarkers, ECG, echocardiography with LVEF and strain) to detect subclinical injury and prevent cardiovascular complications
Guideline-Based Recommendations
Diagnosis
Baseline cardiovascular risk stratification using biomarkers (BNP, troponin), ECG, and echocardiography including LVEF and global longitudinal strain
Use of imaging (mammography, ultrasound, MRI) and biopsy for breast cancer diagnosis and staging
Management
Select anticancer regimens with low cardiotoxicity, avoiding anthracycline-trastuzumab combinations in high-risk patients
Perioperative antithrombotic management balancing thrombotic and bleeding risks using validated scores (PRECISE-DAPT, HAS-BLED)
Implement LMWH bridging therapy when indicated and resume antiplatelet agents early postoperatively with loading doses
Monitoring & Follow-up
Regular cardiac function monitoring every 3 months during treatment including LVEF and cardiac biomarkers
Close surveillance for cardiovascular complications such as myocardial injury, heart failure, and hypertension
Increased risk of heart failure with anthracycline-trastuzumab combinations (16% vs. 1%-3%)
Perioperative stent thrombosis risk highest within 6 months post-PCI, requiring timing consideration for surgery
Bleeding risk assessment essential for safe antithrombotic management
Patient & Prescribing Data
62-year-old female with HER2-positive breast cancer and cardiovascular comorbidities including HTN, DM, and CHD post-PCI
PTD regimen chosen to reduce cardiotoxicity; clopidogrel discontinued 5 days pre-surgery with LMWH bridging; early postoperative resumption of antiplatelets; no cardiovascular complications observed
Clinical Best Practices
Multidisciplinary team involvement for individualized treatment planning balancing oncologic efficacy and cardiovascular safety
Comprehensive baseline cardiovascular evaluation prior to anticancer therapy initiation
Dynamic and regular cardiac monitoring to detect early subclinical cardiotoxicity
Perioperative antithrombotic strategy guided by validated bleeding and thrombosis risk scores
Use of radiotherapy techniques minimizing cardiac radiation exposure
